Data Sheet

Product Name:	Tasimelteon
Cat. No.:	CS-5512
CAS No.:	609799-22-6
Molecular Formula:	$C_{15}H_{19}NO_2$
Molecular Weight:	245.32
Target:	Melatonin Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Solubility:	DMSO : ≥ 33 mg/mL (134.52 mM)



BIOLOGICAL ACTIVITY:

Tasimelteon (BMS-214778) is an orally active and selective **dual melatonin receptor agonist (DMRA)**. Tasimelteon has 2.1-4.4 times greater affinity for the MT2 receptor than for the MT1 receptor. Tasimelteon is a circadian regulator and has the potential for Non-24-Hour Sleep-Wake Disorder (Non-24)[1][2]. **In Vitro:** Tasimelteon (BMS-214778) has 2.1-4.4 times greater affinity for the MT2 receptor believed to mediate circadian rhythm phase-shifting (K_i=0.0692 nM and K_i=0.17 nM in NIH-3T3 and CHO-K1 cells, respectively), than for the MT1 receptor (Ki=0.304 nM and Ki=0.35 nM, respectively). Tasimelteon has no appreciable affinity for more than 160 other pharmacologically relevant receptors and several enzymes[1].

References:

[1]. Christian Lavedan, et al. Tasimelteon: a selective and unique receptor binding profile. Neuropharmacology. 2015 Apr;91:142-7.

[2]. Keating GM, et al. Tasimelteon: A Review in Non-24-Hour Sleep-Wake Disorder in Totally Blind Individuals. CNS Drugs. 2016 Mar 22.

CAIndexNames:

Propanamide, N-[[(1R,2R)-2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]-

SMILES:

[H][C@]1(C2=C3C(OCC3)=CC=C2)[C@@](CNC(CC)=O)([H])C1

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 610-426-3128 Fax: 888-484-5008 E-mail: sales@ChemScene.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA